A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

Introduction: BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non-overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. Methods: In this multicenter, phase 1, 3+3 dose-escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28-day ibrutinib run-in (420 mg daily), then added lenalidomide with intra-patient escalation to a cohort-assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Results: Twenty-seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow-up of 50.4 months, median progression-free survival was 69.5 months (95% CI 53.4-NE). Conclusion: Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. Trial Registration: ClinicalTrials.gov identifier: NCT01886859.

Authors

Institutions

Publication Details

Journal
eJHaem
Published
2026-11-16
DOI
https://doi.org/10.1002/jha2.70463
Primary Topic
Chronic Lymphocytic Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer Ann Woyach, Amy J. Johnson, Daniel Aaron Pollyea, Steven Michael Bair et al.
eJHaem
Chronic Lymphocytic Leukemia Research
article

A Phase 1, Dose Escalation Study of Lenalidomide and Ibrutinib for Relapsed/Refractory Chronic Lymphocytic Leukemia

Jennifer Ann Woyach, Amy J. Johnson, Daniel Aaron Pollyea, Steven Michael Bair, Kerry Anne Rogers, Michael R. Grever, Bita Fakhri, Jonathan Gutman, Steven E Coutré, Manali Kamdar, Mitchell Phelps, John C. Byrd
article en

Abstract

Introduction: BTK inhibitors have transformed the treatment of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), but strategies to deepen and prolong response are needed. Lenalidomide is active in CLL/SLL through a non-overlapping mechanism but is limited by toxicity. We evaluated lenalidomide combined with ibrutinib in relapsed/refractory (R/R) CLL/SLL. Methods: In this multicenter, phase 1, 3+3 dose-escalation study, patients with R/R CLL/SLL after ≥ 1 prior therapy received a 28-day ibrutinib run-in (420 mg daily), then added lenalidomide with intra-patient escalation to a cohort-assigned maximum of 2.5, 5, 7.5, or 10 mg daily. Lenalidomide was stopped after 12 cycles; ibrutinib continued until progression or intolerance. The primary endpoint was safety, tolerability, and maximum tolerated dose (MTD). Results: Twenty-seven patients were enrolled. The MTD of lenalidomide was 5 mg daily. Dose interruptions or reductions occurred in 85% of patients; 7 (26%) and 5 (19%) discontinued for toxicity and progression, respectively. Significant cardiac toxicity occurred in 26%, including heart failure and ventricular arrhythmia (2 patients [7%] each). The overall response rate was 88% (13% complete response). After a median follow-up of 50.4 months, median progression-free survival was 69.5 months (95% CI 53.4-NE). Conclusion: Lenalidomide plus ibrutinib is effective in R/R CLL/SLL but carries an unexpectedly high risk of cardiac toxicity. Trial Registration: ClinicalTrials.gov identifier: NCT01886859.

eJHaemVol. 7(6)
University of Colorado Anschutz Medical Campus (US), The Ohio State University (US), University of Cincinnati (US), Stanford University (US)
National Cancer Institute
Good health and well-being
Chronic Lymphocytic Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon